ABT will do fine as a long-term hold, IMO. It has a moderate valuation and all of its main businesses (branded generic drugs, diagnostics, vascular and ophthalmic devices, nutritional products) are strong beneficiaries of The Global Demographic Tailwind. ABT is one company where investors don’t have to be unduly concerned about quarterly results.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”